AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart Association (AHA) Scientific Sessions 2018 in Chicago, showing that the drug “significantly reduced” hospitalisation or death arising from cardiovascular (CV) conditions in a broad patient population.
The findings were derived from the DECLARE trial, the largest SGLT2 inhibitor CV outcomes study ever conducted, encompassing more than 17,000 participants.
